select
antimicrobi
therapi
suspect
infect
critic
ill
patient
import
decisionmak
process
intensivist
current
age
multidrugresist
organ
mdro
intensivist
must
balanc
increas
mortal
associ
delay
therapi
microbiolog
document
infect
potenti
ecolog
damag
caus
antimicrobi
medic
includ
select
develop
mdro
patient
septic
shock
even
delay
hour
administr
appropri
antimicrobi
therapi
defin
antibiot
regimen
caus
pathogen
sensit
associ
increas
mortal
concept
appli
type
document
infect
pneumonia
bloodstream
infect
administr
inappropri
initi
antibiot
regimen
associ
increas
risk
death
mitig
treatment
escal
unfortun
appropri
initi
antibiot
regimen
becom
increasingli
difficult
due
rise
level
bacteri
resist
escal
rate
antibiot
resist
includ
resist
carbapenem
colistin
becom
increasingli
preval
significantli
impact
morbid
mortal
cost
relat
infect
hospit
patient
especi
intens
care
unit
icu
europ
preval
carbapenemaseproduc
enterobacteriacea
increas
particular
rapid
spread
carbapenemhydrolys
new
delhi
metallobetalactamaseproduc
enterobacteriacea
antimicrobi
use
key
determin
select
resist
bacteria
wherebi
increas
daili
cumul
exposur
especi
carbapenem
increas
likelihood
intestin
carriag
mdro
rapid
evolut
antibiot
resist
imped
effort
insur
initi
appropri
antibiot
therapi
deliv
critic
ill
infect
patient
rise
rate
antibiot
resist
like
contribut
increas
observ
mortal
attribut
antibioticresist
bacteria
despit
overal
reduct
death
ascrib
infecti
diseas
last
centuri
acinetobact
baumannii
pseudomona
aeruginosa
repres
two
import
mdro
due
extent
antimicrobi
resist
intrins
virul
especi
pseudomona
abil
establish
within
hospit
environ
icu
infect
immun
suppress
host
inde
recent
european
task
forc
recommend
empir
use
polymixin
colistin
part
empir
antimicrobi
regimen
infect
baumannii
suspect
due
high
rate
carbapenem
resist
pathogen
import
contributor
escal
rate
infect
mdro
especi
europ
north
america
popul
migrat
middl
east
part
asia
africa
similarli
movement
individu
across
border
also
recogn
import
sourc
spread
emerg
infect
dengu
fever
zika
viru
middl
east
respiratori
syndrom
coronaviru
reduc
unnecessari
use
antibiot
seen
pivot
strategi
curtail
emerg
spread
mdro
figur
provid
summari
strategi
antimicrobi
deescal
assist
intensivist
balanc
desir
treat
appropri
antibiot
regimen
need
avoid
unnecessari
antibiot
exposur
accumul
recent
evid
rate
catheterrel
infect
cri
substanti
reduc
toward
zero
correct
applic
care
bundl
recent
summar
intens
care
medicin
cornerston
prevent
reli
correct
skin
prepar
alcohol
seem
mandatori
antisepsi
solut
due
rapid
activ
chlorhexidin
glucon
ensur
prolong
bactericid
effect
actual
import
certaintiesrecommend
prevent
cri
like
applic
steril
disinfect
skin
prior
insert
vascular
cathet
need
clean
skin
soap
deterg
antisept
applic
obvious
dirti
contamin
rins
steril
water
recommend
antisept
applic
singleus
vial
disinfect
solut
prefer
multipleus
bottl
daili
evalu
necess
retain
central
line
remov
clinic
longer
necessari
nonadher
soil
moisten
dress
prompli
replac
subclavian
site
insert
prefer
unless
otherwis
contraind
full
barrier
precaut
use
insert
hand
hygien
alcohol
solut
mandatori
everi
manipul
everi
unit
adopt
written
protocol
cathet
insert
mainten
certainli
room
improv
behavior
approach
requir
welldesign
multin
trial
howev
mortal
cri
rate
reduc
prospect
random
control
studi
brazil
employ
behavior
approach
retent
withdraw
central
line
rather
short
evalu
period
might
contribut
nevertheless
feedback
administr
caregiv
posit
prompt
univers
adopt
program
experiment
period
month
transpar
antimicrobi
dress
significantli
efficaci
prevent
crbsi
compar
refer
dress
use
steril
isopropyl
alcohol
skin
antisepsi
repres
new
standard
care
sourc
control
recommend
within
h
patient
admiss
includ
primarili
action
taken
process
care
control
foci
infect
gain
import
pivot
measur
improv
patient
outcom
particularli
intraabdomin
skin
soft
tissu
implantassoci
infect
cri
edusepsi
studi
conduct
spanish
icu
patient
underw
sourc
control
older
greater
preval
shock
major
organ
dysfunct
bacteremia
inflammatori
marker
lactic
academia
wors
complianc
resuscit
bundl
compar
undergo
sourc
control
sourc
control
group
lower
crude
icu
hospit
mortal
even
adjust
confound
factor
sourc
control
perform
h
associ
higher
mortal
impli
highrisk
patient
even
beyond
timefram
admiss
may
contribut
improv
outcom
anoth
spanish
retrospect
cohort
intraabdomin
candidiasi
iac
sourc
control
along
earli
antifung
treatment
associ
improv
surviv
icu
surgic
ward
stand
main
goal
decreas
mortal
iac
episod
insid
outsid
icu
invas
candidiasi
ic
compris
bloodstream
deepseat
invas
infect
due
candida
speci
repres
major
caus
morbid
mortal
remain
near
seri
past
decad
incid
ic
shown
progress
increas
stabl
rate
region
probabl
due
grow
complex
surgic
procedur
presenc
patient
popul
higher
risk
infect
chang
patient
demograph
characterist
attribut
mortal
around
report
sever
studi
recent
welldesign
studi
conduct
india
report
rate
around
infectionrel
morbid
mortal
associ
ic
part
associ
critic
ill
may
also
attribut
suboptim
diagnost
tool
standard
mycolog
convent
blood
cultur
gold
standard
may
fail
diagnos
ic
wherea
time
posit
yeast
speci
identif
take
sever
day
time
blood
cultur
drawn
depend
implic
candida
speci
unless
antifung
therapi
promptli
initi
confirm
ic
effect
antifung
therapi
may
delay
numer
studi
demonstr
delay
initi
antifung
therapi
associ
signific
increas
inhospit
mortal
cost
care
patient
ic
candidemia
episod
easier
recogn
diagnos
compar
deepseat
candidiasi
current
guidelin
mainli
focu
manag
candidemia
trial
iac
lack
risk
factor
iac
includ
recent
surgeri
necrot
pancreat
anastomot
leak
empir
antifung
treatment
echinocandin
lipidformul
amphotericin
b
consid
critic
ill
patient
previou
exposur
azol
risk
factor
candida
spp
infect
despit
lack
random
trial
antifung
therapi
patient
complic
intraabdomin
infect
recommend
candida
spp
grown
cultur
sever
abdomin
condit
nonneutropen
critic
ill
patient
high
level
combin
candida
albican
germ
tube
antibodi
may
help
clinician
discrimin
candida
spp
colon
ic
sourc
control
shown
import
determin
outcom
patient
candidemia
iac
base
expert
guidelin
previou
studi
central
venou
cathet
withdraw
attempt
identifi
collect
rapidli
appropri
drain
case
ic
treatment
given
immedi
thereaft
would
import
step
earli
triazol
deescal
echinocandin
intraven
oral
fluconazol
encourag
patient
clinic
stabl
isol
strain
suscept
exact
time
shift
fluconazol
well
establish
may
vari
depend
patient
pathogenrel
factor
safeti
deescal
within
day
case
proven
probabl
ic
recent
suggest
nonneutropen
patient
treat
icu
sinc
associ
increas
mortal
led
subsequ
signific
decreas
antifung
consumpt
remark
rule
develop
antifung
stewardship
program
target
antifung
treatment
bundl
report
electron
supplement
materi
